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Abstract
Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of
children with bipolar disorders suffering from manic symptomatology.
Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score15) meeting strict, unmodified, Diagnostic
and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4–9 years,
were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16
weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-
Severity, Children’s Global Assessment Scale (CGAS), and the Children’s Depression Rating Scale-Revised (CDRS-R). A
priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R <29; (2) YMRS <10; and (3) CGAS >50.
Results: Ninety-six children (62 males; mean age of 6.9 (SD¼ 1.7), received APZ for an average length of treatment of 12.5
(SD¼ 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity
scores ( p< 0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at
study’s end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were
removed from the study due to side effects [epistaxis (n¼ 1); akathisia (n¼ 1)]. Subjects experienced an average weight gain
of 2.4 (SD¼ 1.9) kg.
Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.
Introduction
In recent multi-site, pharmaceutical industry-sponsoredstudies, the treatment of manic and mixed states in pediatric
bipolar disorder has generally focused on patients between the ages
of 10–17 years (DelBello et al. 2007, 2008; Tohen et al. 2007;
Findling et al. 2009b; Haas et al. 2009). The selection of this age
range for these trials was likely the result of implementing the
recommendations that were generated as part of a consensus
meeting that suggested this age range be used in industry-sponsored
research studies in this patient population (Carlson et al. 2003).
However, in research populations that have included children
younger than age 10, pediatric bipolar disorders have been shown to
be serious illnesses (Wozniak et al. 1995; Findling et al. 2001;
Geller et al. 2004; Axelson et al. 2006). For these reasons, recent
treatment guidelines have supported the judicious use of pharma-
cological treatment for these younger children (Kowatch et al.
2005).
Aripiprazole (APZ) is an atypical antipsychotic that has been
reported to have both acute (Tramontina et al. 2009; Findling et al.
2009b) and long-term (Wagner et al. 2007) efficacy in the treatment
of children (aged 8 to 17 years) with manic or mixed states. In 2008,
the U.S. Food and Drug Administration (FDA) approved the use of
APZ for the acute treatment of manic or mixed states in pediatric
patients (aged 10 to 17 years). Additionally, use of APZ as either
maintenance therapy or as an adjunct to treatment with lithium or
valproate for manic or mixed episodes associated with bipolar I
disorder (BP-I) is FDA-approved in this population, based on ex-
trapolation from adult efficacy data. Past pediatric research that has
included patients under the age of 10 has suggested that APZ might
be a reasonable treatment option in this age group. In a prospective,
open-label study that included 12 children (ages 6–12 years) with
conduct disorder, APZ was found to be effective and reasonably
well tolerated (Findling et al. 2009a). Additionally, retrospective
reviews of APZ monotherapy and APZ as adjunctive therapy have
reported symptom amelioration in children and adolescents aged 4
to 19 years with bipolar and bipolar spectrum disorders (Barzman
et al. 2004; Biederman et al. 2005).
Based on the extant evidence when this study was designed, it
appeared that APZ was a compound worthy of further investigation
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in symptomatic children younger than age 10 years suffering from
bipolar illnesses. The purpose of this study was to describe the
safety and effectiveness of APZ in children 4 to 9 years of age with
bipolar illnesses who were currently suffering from elevated
symptoms of mania. It was hypothesized that APZ monotherapy
would be generally well tolerated and associated with symptom
reduction in this patient population.
Methods
The University Hospitals Case Medical Center Institutional
Review Board for Human Investigation approved the procedures of
this outpatient, single-site study. Written informed consent was
provided by all parents/guardians of study participants. Oral assent
was provided by all children participating in the study.
After the baseline visit, youth were seen weekly for the first 4
weeks, then biweekly thereafter. The length of study participation
could last up to 16 weeks. Once participants met a priori stabili-
zation criteria (treatment with APZ for a minimum of 6 weeks and 3
of 4 consecutive weeks with: Children’s Depression Rating Scale-
Revised (CDRS-R)< 29; Young Mania Rating Scale (YMRS)
<10; and Children’s Global Assessment Scale (CGAS) >50) these
children were withdrawn from this protocol and were offered en-
rollment in an ongoing randomized, double-blind, placebo-con-
trolled discontinuation trial that was examining the efficacy of APZ
in this patient population. Youth who participated in the present
trial but (1) did not meet a priori response criteria; (2) were unable
to tolerate the study medication; or (3) withdrew from this trial for
any other reason were not eligible for enrollment into the afore-
stated discontinuation study.
Subjects
Outpatient children aged 4–9 years meeting Diagnostic and
Statistical Manual of Mental Disorders, 4th edition, criteria
(American Psychiatric Association 2000) for a diagnosis of BP-I,
BP-II, Bipolar Disorder NOS (BP-NOS), or Cyclothymia were
eligible to enroll. Children who experienced spontaneous, dys-
functional manic episodes that did not meet full criteria for any
other mood disorder were given the diagnosis of BP-NOS, as we
have done in our prior work (Findling et al. 2005). The decision to
include children with BP-NOS and cyclothymia was informed by
finding that youth who suffer from these diagnoses who are seen at
this center have substantial mood symptomatology and impairment
(Findling et al. 2005), consistent with other studies (Axelson et al.
2006).
Patients were initially screened by highly trained interviewers
completing the Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children interview (K-SADS-PL; Kauf-
man et al. 1997). Doctor’s-level, master’s-level, or bachelor’s-level
interviewers administered the K-SADS interviews. Inter-rater re-
liability on the K-SADS was assessed with the kappa (k) statistic.
Before leading a K-SADS interview, all interviewers demonstrated
adequate inter-rater reliability (k 0.85) and diagnostic assess-
ment agreement based on the results of five K-SADS interviews.
Subsequently, inter-rater reliability was maintained (k 0.85) by
conducting joint assessments. A previous study of the inter-rater
reliability of K-SADS diagnoses reported high reliability (k¼ 1.00)
in children aged 4 to 10 years (Frazier et al. 2007).
Youth also received a separate clinical evaluation by a board-
certified or board-eligible child and adolescent psychiatrist to
confirm the bipolar diagnosis obtained based on the results of the K-
SADS assessment. Further, all enrolled youth had an YMRS score
of 15 at the baseline visit, indicative of clinically significant
manic symptomatology (Young et al. 1978).
Children were excluded from participating in this trial if they
had a history of intolerance to APZ at doses of 0.1 mg/kg/day or
were allergic to APZ. Children who experienced a manic episode
with 0.2 mg/kg/day of APZ monotherapy were excluded. Those
youth who in the clinical judgment of the evaluating physician had
a pervasive developmental disorder, mental retardation, or a gen-
eral medical or neurological condition for which treatment with
APZ would be contraindicated were excluded. In addition, youth
taking psychotropics within 1 week of baseline, or psychostimu-
lants within 3 days of baseline, were not included in this study.
Screening period
Before the baseline assessment, patients received a physical
examination, an electrocardiogram (ECG), and screening labora-
tories (see below). During the screening process, information about
subject demographics and clinical characteristics was obtained. For
some subjects, screening and baseline occurred on the same day.
For the sake of convenience, screening and baseline procedures
could be split among more than one visit to reduce subject/family
burden. The pretreatment screening period did not last longer than 4
weeks.
Pharmacotherapy
Results from a previous open-label study of APZ informed the
dosing design utilized in the present study (Findling et al. 2009a).
All youth received an initial APZ dose of *0.1 mg/kg/day, and
were titrated, per protocol, in a flexible-dose manner based upon
tolerability and effectiveness. The entire dose of APZ was to be
administered at bedtime. However, morning or BID dosing was
permissible to maximize clinical benefits while minimizing side
effects. APZ could be increased to *0.15 mg/kg/day at end of
week 1, and could again be increased to the maximum dose of
*0.2 mg/kg/day at the end of week 2. After 3 weeks of treatment,
patients with residual symptomatology and no intolerable side ef-
fects could have their dose increased to a total daily dose of
*0.25 mg/kg/day. Patients tolerating *0.25 mg/kg/day could
have their dose increased to a total daily dose of *0.3 mg/kg/day at
the end of week 4 if clinically indicated. However, the maximum
total daily dose was set at 15 mg/day for all patients. APZ could be
lowered at any time due to safety or tolerability issues. Those youth
who experienced significant adverse effects at an APZ dose of
0.05 mg/kg/day were considered intolerant to APZ, and were re-
moved from the study.
Youth who had received APZ for at least 6 weeks, and were
determined to be responders as defined by the a priori criteria, yet
still met Diagnostic and Statistical Manual of Mental Disorders,
4th edition, criteria for attention-deficit/hyperactivity disorder
(ADHD) (American Psychiatric Association 2000) could be of-
fered adjunctive psychostimulants. Youth could be treated in an
open-label fashion with either methylphenidate-based preparations
or amphetamine-based preparations at FDA-approved dosages for
children, at the discretion of the treating physician. Treatment with
other psychotropic medications was not permitted in this study.
Outcome measures
Youth were evaluated by a child and adolescent psychiatrist and
trained rater at every visit. The clinical rating scales used included
the YMRS (Young et al. 1978); CDRS-R (Poznanski et al. 1985);
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Clinical Global Impressions Scale-Severity (CGI-S) (NIMH
1985b); and the CGAS (Shaffer et al. 1983). Master’s-level or
bachelor’s-level interviewers administered the YMRS and CDRS-
R. Before leading a YMRS or CDRS-R interview independently,
all raters needed to rate along with a qualified interviewer for five
interviews and lead five interviews while demonstrating exact
agreement with the experienced interviewer on at least 50% of the
items with the other 50% of items differing by no more than one
point. Both the YMRS and CDRS-R have demonstrated strong
reliability and measure symptoms consistently across a wide range
of ages (4 to 17 years) in pediatric bipolar disorder (Frazier et al.
2007).
Safety monitoring
Monitoring of side effects occurred at each visit by open-ended
inquiry of physical, emotional, behavioral, and cognitive changes
noted by both subject and parent/guardian. In addition, each youth
at every visit was evaluated using the Abnormal Involuntary
Movement Scale (NIMH 1985a), the Barnes Akathisia Scale (BAS)
(Barnes 1989), and the Neurological Rating Scale (NRS) (Simpson
and Angus 1970). The NRS was supplemented with three addi-
tional items to assess cogwheeling, acute dystonic reaction, and
subjective sense of stiffness.
Before study medication initiation, each youth received a
physical examination, ECG, weight, height, blood pressure, and
pulse measurements. Laboratory tests before dosing included uri-
nalysis, research chemistry panel including fasting glucose and
fasting lipid profile, complete blood count with platelets and dif-
ferential, lead level, prothrombin time/partial thromboplastin time,
prolactin concentration, and thyroid-stimulating hormone. La-
boratory measures (except for the lead level, prothrombin time/
partial thromboplastin time, and thyroid-stimulating hormone)
were repeated at week 6 and week 16/end of study (EOS) partici-
pation. Weight, blood pressure, and pulse were assessed at each
visit, whereas height and ECG measurements were repeated at
week 6 and week 16/EOS participation.
Statistical analysis
Analyses were performed using the Statistical Package for the
Social Sciences for Windows (SPSS, version 16.0). Averages are
presented as mean (standard deviation) unless otherwise noted. The
data were considered adequately close to normally distributed if
both skewness and kurtosis of the data were <3.0. Skewness
measures the symmetry of the score distribution and indicates
whether there were extreme high or low scores; kurtosis indicates
whether the distribution was normal shaped versus having thicker
tails or more bunching in the mid-range. Using an intent-to-treat
analysis with last observation carried forward, paired samples t-
tests were used to compare YMRS, CGAS, and CGI-S scores at
baseline with end of week 6 and EOS participation scores. CDRS-R
scores at baseline, week 6, and EOS CDRS-R scores as well as EOS
weight was compared with baseline weight using the Wilcoxon
Signed Ranks Sum Test because the data were not normally dis-
tributed. Fisher’s Exact Tests were used to determine differences in
the occurrences of side effects between those patients that were
considered responders and those patients who did not meet re-
sponse criteria. In addition, fasting glucose, fasting cholesterol,
triglycerides, and prolactin levels at baseline and EOS were com-
pared using paired samples t-tests.
A chi-square analysis was used to detect differences in the dis-
tribution of males and females who met response criteria. Also, age,
bipolar diagnosis, comorbid diagnosis, age at onset of symptoms,
length of illness, length of treatment, and baseline symptom se-
verity were compared in patients considered responders at the EOS
and nonresponders using independent sample t-tests. Standardized
effect sizes were calculated using Cohen’s d (Cohen 1988). The
level of significance was set at 0.05 for all analyses. Due to the
exploratory nature of this trial, the alpha level for statistical sig-
nificance was not adjusted for the multiple comparisons performed.
Results
Subjects
One hundred forty subjects were screened for possible partici-
pation in this treatment study between May of 2004 and November
of 2008. Of these subjects, 96 were enrolled, prescribed study
medication, and returned after at least 1 week of treatment (Fig. 1).
Fourty-four of the 140 screened patients did not receive study
medication due to not meeting study inclusion/exclusion criteria
(n¼ 19); withdrawing consent before dosing (n¼ 14); and study
nonadherence (i.e., lost to follow-up) (n¼ 11). Demographics for
the 96 subjects who were prescribed study medication are described
in Table 1. Of the 96 participating subjects, 83 (86.5%) met diag-
nostic criteria for comorbid ADHD.
These 96 subjects participated in the study for a mean of 12.5
weeks (SD¼ 3.9), with a range of 2.0–18.1 weeks. Three partici-
pants remained in the study for approximately one additional week
and another child for two additional weeks owing to scheduling
difficulties.
Symptom response
Baseline mood states of these 96 subjects are listed in Table 2.
Subjects who presented as mixed at baseline did not differ in length
of time in study compared with children who were manic or hy-
pomanic at baseline (t¼ 1.56, df¼ 94, p¼ 0.12). Significant de-
creases in the YMRS, CDRS-R, CGI-S, and CGAS were found
after 6 weeks of treatment with APZ and at the EOS (all p-values
<0.001; See Table 3). The effect size of the change in YMRS,
CDRS-R, CGI-S, and CGAS scores after 6 weeks of treatment with
APZ and at the EOS are also included in Table 3. Overall effects
were very large (d> 2.00) for YMRS, CGI-S, and CGAS outcomes
and medium to large (d¼ 0.68–0.69) for CDRS-R outcomes at 6-
weeks and EOS.
140 Patients Screened 
96 Patients Dosed and 
Returned for Post 
Dose Evaluation 
60 Patients Completed 
the Study and Met 
Response Criteria  
Did not meet study inclusion/exclusion 
criteria (n=19) 
Withdrew Consent (n=14) 
Study Non-compliance (n=11) 
Withdrew Consent (n=5) 
Study Non-compliance (n=7) 
Medication Non-compliance (n=2) 
Lack of Efficacy- Hypomania (n=9) 
Lack of Efficacy- Mixed States (n=4) 
Lack of Efficacy- Continued Cycling (n=3) 
Lack of Efficacy- Mania (n=2) 
Lack of Efficacy- Depression (n=1) 
Hospitalized for aggressive behavior (n=1) 
Discontinued due to an adverse event (n=2: 
epistaxis n=1; akathisia n=1) 
FIG. 1. Subject accountability flowsheet.
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Study participation and clinical response
Of the 96 subjects who received study medication, 60 (62.5%)
completed participation in the trial and were considered responders.
The average length of treatment for these responders was 14.3 (2.6)
weeks, with a range of 5.9–17.1 weeks. The average treatment
duration for the 36 (37.5%) subjects who did not meet response
criteria at EOS was 9.6 weeks (3.9), with a range of 2.0–18.1 weeks.
Medication dosing at EOS participation
The average dose of APZ for the entire cohort at EOS was
6.5 mg/day (2.3 mg/day). Youth considered responders received a
mean dose of APZ 6.4 mg/day (2.1 mg/day) and those youth who
were nonresponders received a mean APZ dose of 6.8 mg/day
(2.6 mg/day) during their last week of participation. Thirty-two
(34.4%) of the 93 subjects who completed 6 weeks of study par-
ticipation received treatment with an adjunctive psychostimulant.
Medication tolerability
No subjects experienced/reported suicidal ideation or made a
suicidal gesture/attempt, and there were no deaths fron any cause.
One study participant discontinued the medication due to epistaxis
and another subject discontinued after developing akathisia. The
most common adverse events experienced by the study participants
were stomachache (n¼ 40), headache (n¼ 38), and increased ap-
petite (n¼ 38) (Table 4). In addition, there was no difference in the
occurrence of the most commonly reported adverse events between
the children who were considered responders and those considered
nonresponders (all p-values >0.05, Table 4).
Three subjects scored a ‘‘1’’ on the NRS, indicative of mild
severity (two subjects at week 1 and one subject at weeks 2 and 3).
In addition, one subject who scored a ‘‘1’’ on the NRS at week 1
scored a ‘‘1’’ on the additional cogwheeling item on the NRS.
Another subject scored a ‘‘1’’ on the BAS, indicative of mild in-
tensity, at week 12. Finally, the subject that discontinued the study
due to akathisia had a BAS total score of 7 three days before ending
study and a BAS total score of 5 at EOS. All other subjects scored
‘‘0’’ on all items of the SARS, BAS, and Abnormal Involuntary
Movement Scale throughout the course of the entire study.
Weight changed by a mean of 2.4 kg (1.9 kg), ranging from
0.68 to 7.7 kg. The children treated in this study had a significant
increase in weight at the end of the study (mean predose
weight¼ 26.9 kg (8.7), EOS weight¼ 29.3 kg (9.6); p< 0.001). No
significant differences between baseline and EOS fasting glucose
(t¼ 1.31, df¼ 73, p¼ 0.194) and fasting cholesterol (t¼ 0.83,
df¼ 74, p¼ 0.408) (Table 5) were found. In addition, no clinically
significant changes in laboratory measures, pulse, blood pressure,
or QTc measurements on ECG were noted. Prolactin levels de-
creased at EOS compared with baseline levels (t¼ 10.82, df¼ 83,
p< 0.001) and fasting triglyceride levels (t¼ 2.67, df¼ 74,
p< 0.01) (Table 5) were found to increase.
Factors associated with response
Sex, age, and the number of patients with BP-I were not signifi-
cantly different between the responder and nonresponder groups.
Age at symptom onset and mean duration of symptoms were not
statistically different between responders compared with nonre-
sponders. Responders were found to be enrolled in the study for a
longer period than the nonresponders (t¼ 7.15, df¼ 94, p< 0.001).
Baseline CDRS-R scores significantly differed between re-
sponders [mean¼ 23.4 (4.8)] and nonresponders [mean¼ 28.0
(7.1); t¼ 3.79, df¼ 94, p< 0.001], with nonresponders having a
significantly higher baseline CDRS-R score compared with the
responders. Additionally, although baseline YMRS scores did not
reach significance, a trend was found (t¼ 1.94, df¼ 94, p¼ 0 0.06)
for responders to have lower baseline YMRS scores [mean¼ 23.0
(4.9)] compared with the nonresponders [mean¼ 25.2 (5.6)].
However, CGI-S and CGAS scores were not significantly different
between those patients that met response criteria and those patients
that were considered nonresponders ( p-values> 0.05). The mean
weight adjusted APZ doses at EOS did not differ between re-
sponders [mean¼ 0.23 mg/kg (0.07)] and nonresponders
[mean¼ 0.24 mg/kg (0.09): t¼ 1.05, df¼ 94, p¼ 0.30].
Discussion
These preliminary data suggest that there are children aged 4–9
years with bipolar illness and elevated symptoms of mania who
may acutely benefit from APZ therapy. Both mania (YMRS) and
depression (CDRS-R) rating scales scores decreased significantly.
Overall, APZ was found to be generally safe and well tolerated.
The extrapyramidal side effects experienced in this study were
found to be mild, with only one child discontinuing the study due to
akathisia. Only one other child ended the study due to an adverse
event, epistaxis. Other side effects were generally transient and of
modest severity with the most frequently reported adverse events
experienced in this study being stomachache, increased appetite,








Males (%) 62 (65%) 42 (70%) 20 (56%)
Mean age (SD) 6.9 (1.7) 6.9 (1.6) 6.9 (1.8)
Primary diagnosis
Bipolar I 41 (43%) 21 (35%) 20 (56%)
Cyclothymia 8 (8%) 6 (10%) 2 (6%)
Bipolar disorder not
otherwise specified





83 (87%) 54 (90%) 29 (81%)
Oppositional defiant
disorder
20 (21%) 11 (18%) 9 (25%)
Conduct disorder 2 (2%) 1 (2%) 1 (3%)
Mean age at onset
of bipolar
symptoms (years)
3.7 (1.8) 3.6 (1.7) 3.9 (1.9)
SD¼ standard deviation.









Mixeda 23 (24%) 11.4 (4.4) 8 (35%)
Manic/hypomanicb 73 (76%) 12.9 (3.6) 52 (71%)
aChildren’s Depression Rating Scale-Revised (CDRS-R) >28 and
Young Mania Rating Scale (YMRS) 12
bManic¼CDRS-R 28 and YMRS 16 (n¼ 69); Hypomanic¼
CDRS-R 28 and YMRS 12–15 (n¼ 4).
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headache, sedation, and emesis. Using two or more study visits as a
metric of persistence, 24 subjects experienced persistent sedation,
and 7 subjects experienced persistent nausea/emesis.
Fasting glucose and cholesterol did not change significantly
during the course of this study. No clinically significant cardiovas-
cular effects, in the treating physicians’ clinical judgment, were
observed. However, fasting triglycerides were found to significantly
increase, whereas prolactin levels were found to decrease, at the EOS
in comparison to pretreatment levels. In addition, significant weight
gain was found in this sample. Because of these tolerability concerns
and the relative paucity of data about APZ in this patient population,
whether or not the risk/benefit ratio associated with APZ treatment
justifies prescribing this medication to an individual patient deserves
careful consideration by the treating clinician.
Nonresponse
Despite significant clinical benefit for the sub-cohort of youths
who completed the protocol, 38% of the sample was nonrespond-
ers, most commonly due to medication noncompliance and/or
continued symptomatology. There are several factors that may
account for this nonresponse rate. Nonresponders remained in the
study for less time due to study noncompliance and continued
symptomatology. Also, those who did not respond had significantly
more depressive symptoms and, although not statistically signifi-
cant, more severe manic symptomatology compared with those
who responded.
Further, dosing may have been inadequate in the nonresponder
group. Although the mean final doses of APZ that were prescribed
to responders were not significantly lower than the doses prescribed
to nonresponders, it is quite possible that if a higher maximum total
daily dose of medication were permitted per protocol, some of the
nonresponders might have responded. Data from a retrospective
study of APZ in youth with symptoms of mania reported doses of
16 7.9 mg in youth ages 11.4 3.5 years (Biederman et al. 2005).
Similarly, higher APZ doses were found to be effective and rea-
sonably well tolerated in a group of youths between the ages of 10
and 17 years in which treatment with APZ was initiated at 2 mg/
day, and then, using a forced titration scheme, increased every 2
days for up to 12 days to achieve a maximum dose of 20, 25, or
30 mg/day (Findling et al. 2008). Additionally, a 30 mg/day APZ
dose was both effective and generally well tolerated in a random-
ized, double-blind, placebo-controlled study in pediatric patients
(ages 10 to 17) with BP-I, currently experiencing a manic or mixed
episode (Findling et al. 2009b).

















Overall 23.8 (5.3) 8.1 (4.9) 3.07 8.5 (6.6) 2.57
Responders 23.0 (4.9) 6.4 (4.3) 3.62 4.9 (3.7) 4.22
Nonresponders 25.2 (5.6) 11.0 (4.7) 2.74 14.6 (6.0) 1.82
CDRS-R
Overall 25.2 (6.1) 21.2 (5.2) 0.69 21.4 (5.0) 0.68
Responders 23.4 (4.8) 20.0 (3.3) 0.85 19.4 (2.6) 1.09
Nonresponders 28.0 (7.1) 23.3 (6.9) 0.68 24.7 (6.0) 0.50
CGAS
Overall 53.3 (5.5) 66.7 (6.6) 2.20 67.9 (8.7) 2.07
Responders 53.0 (4.9) 68.0 (6.4) 2.65 72.1 (6.2) 3.44
Nonresponders 53.7 (6.5) 64.2 (6.5) 1.62 60.5 (7.4) 0.99
CGI-S
Overall 4.0 (0.7) 1.9 (0.7) 2.94 1.9 (0.9) 2.54
Responders 3.9 (0.7) 1.7 (0.7) 3.21 1.5 (0.6) 3.74
Nonresponders 4.0 (0.6) 2.2 (0.8) 2.68 2.7 (0.9) 1.81
M¼Mean; EOW 6¼End of Week 6; EOS¼End of Study; CGAS¼Children’s Global Assessment Scale; CGI-S¼Clinical Global Impressions Scale-
Severity.








Stomachache 40 (42%) 24 (40%) 15 (42%) 1.000
Increased appetite 38 (40%) 26 (43%) 12 (33%) 0.392
Headache 38 (40%) 25 (42%) 13 (36%) 0.669
Sedation 33 (34%) 24 (40%) 9 (25%) 0.183
Emesis 33 (34%) 22 (37%) 9 (25%) 0.267
Cold symptoms 24 (25%) 18 (30%) 6 (17%) 0.223
Weight gain 18 (19%) 12 (20%) 6 (17%) 0.791
Cough 17 (18%) 14 (23%) 3 (8%) 0.096
Fever 16 (17%) 12 (20%) 4 (11%) 0.397
Nasal congestion 16 (17%) 12 (20%) 3 (8%) 0.156
Musculoskeletal
pain
12 (13%) 9 (15%) 3 (8%) 0.526
Table 5. Mean Physiologic Measurements for Subjects
Measure Pretreatment EOS
Prolactin (mg/L), n¼ 84 5.7 mg/L (3.7) 1.2 mg/L (1.1)
Fasting glucose
(mg/dL), n¼ 74
82.6 mg/dL (8.9) 84.2 mg/dL (13.1)
Fasting cholesterol
(mg/dL), n¼ 75
166.2 mg/dL (28.1) 163.9 mg/dL (28.4)
Fasting triglyceride
(mg/dL), n¼ 75
52.6 mg/dL (29.4) 63.3 mg/dL (35.9)
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The results from both these studies were not available when this
current trial was designed. However, in this preliminary safety
study of young children, the APZ dose was kept intentionally
within the extant evidence to minimize subject risks. In short,
treatment with higher doses of APZ than used in the current study
might be indicated in this patient population; however, this remains
an empiric question that deserves further study.
Limitations
This study has several limitations besides the dosing consider-
ations noted above. It was the intention to include common co-
morbidites (e.g., ADHD and oppositional defiant disorder) in this
study in an effort to allow this sample to be reasonably generaliz-
able. However, the sample enrolled needed to meet explicit in-
clusion and exclusion criteria, and so may not fully represent the
clinical diversity seen in general practice. Further, the open-label
design lacks the methodological stringency of a randomized,
double-blind, placebo-controlled trial. For these reasons, these data
should be considered preliminary. The very large effect sizes
suggest potentially promising efficacy, but a more rigorous trial
will be needed to make stronger inferences and clinical recom-
mendations. In addition, this trial had a limited sample size. As
such, it is possible that uncommon medication-related adverse
events might not have been observed. Also, assertions about the
long-term tolerability and effectiveness of APZ cannot be made due
to the study’s brevity.
Clinical Implications
To our knowledge, this is the first reported prospective study
evaluating the effectiveness and safety of APZ that specifically
treated children under the age of 10 years with bipolar illness.
Although this report provides information in an area of critical
need, more investigation into the use and safety of atypical anti-
psychotics in treating pediatric bipolar disorder would further in-
form clinical practice. These findings suggest that, using the dosing
strategy employed in this trial, APZ monotherapy may be a safe and
effective acute treatment option for bipolar disorder in a population
of 4–9-year-old children. Further clinical research including studies
that incorporate randomized, double-blind, placebo-controlled de-
signs appear to be indicated. Studies that examine APZ dosing
strategies, which might include higher APZ doses than employed
herein, should also be considered to determine the most effective
dosing paradigm for these children.
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